A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes

Completed · Phase 1 · Has a placebo group

Conditions studied: Recurrent Genital Herpes Simplex Type 2

In brief

This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-1179 in Part A in healthy participants and multiple-ascending doses (MAD) of ABI-1179 in Part B in participants seropositive for Herpes Simplex Virus Type 2 (HSV-2) with recurrent genital herpes. Effect of food will also be evaluated in Part A.

Key facts

Study ID
NCT06698575
Run by
Assembly Biosciences
People needed
103
Starts
2024-12-08
Expected to finish
2026-01-19
Last updated by the study team
2026-03-23

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.